About
Overview
Leadership
Area of Focus
Congestion in Heart Failure
Outpatient Parenteral Antimicrobial Treatment (OPAT)
Research and Development
FUROSCIX
®
(furosemide injection) for subcutaneous administration
scCeftriaxone
Clinical Development & Medical Affairs
Investor Relations
Investor Overview
Stock Information
Stock Quote & Chart
Historical Price Lookup
Investment Calculator
Corporate Governance
Governance Highlights
Committee Composition
Financial Information
Sec Filings
News & Events
News Releases
Event Calendar
Presentations
Investor Resources
Investor FAQ
Information Request
E-mail Alerts
Ir Contacts
Media Resources
Careers
Contact Us
Legal
Privacy Policy
Terms of Use
scPharmaceuticals
Areas of Focus
Research & Development
Careers
Recent News
May 17, 2022
scPharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
Read More
May 16, 2022
scPharmaceuticals Inc. Reports First Quarter 2022 Financial Results and Provides Business Update
Read More
May 16, 2022
scPharmaceuticals Inc. Announces FDA Acceptance of FUROSCIX
®
New Drug Application
Read More
April 11, 2022
scPharmaceuticals Inc. Announces Resubmission of FUROSCIX
®
New Drug Application
Read More
All News
